

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Comparative efficacy and complication rates after local treatment for cervical intra-epithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028008
Article Type:	Protocol
Date Submitted by the Author:	18-Nov-2018
Complete List of Authors:	<p>Athanasίου, Antonios; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p> <p>Veroniki, Areti Angeliki; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Panepistimio Ioanninon, School of Education, Department of Primary Education</p> <p>Eftimiou, Orestis; University of Bern, Institute of Social and Preventive Medicine (ISPM)</p> <p>Kalliala, Ilkka; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; University of Helsinki and Helsinki University Hospital, Department of Obstetrics and Gynaecology</p> <p>Naci, Huseyin; London School of Economics, Department of Health Policy</p> <p>Lever, Sarah; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p> <p>Paraskevaidi, Maria; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London</p> <p>Martin-Hirsch, Pierre; Lancashire Teaching Hospitals NHS Foundation Trust, Department of Gynaecologic Oncology</p> <p>Bennett, Philip; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p> <p>Paraskevaidis, Evangelos; University of Ioannina and University Hospital of Ioannina, Department of Obstetrics & Gynaecology; Imperial College Healthcare NHS Trust</p> <p>Salanti, Georgia; University of Bern, Institute of Social and Preventive Medicine (ISPM)</p> <p>Kyrgiou, Maria; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p>
Keywords:	"Cervical Intraepithelial Neoplasia/surgery"[Mesh], "Cervical Intraepithelial Neoplasia/therapy"[Mesh], "Treatment Outcome"[Mesh], "Recurrence"[Mesh], "Conization/adverse effects"[Mesh], "Ablation Techniques/adverse effects"[Mesh]

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts

1
2
3 **Comparative efficacy and complication rates after local treatment for cervical intra-**
4 **epithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and**
5 **network meta-analysis from the CIRCLE Group**
6
7

8 Antonios Athanasiou^{1,2}, Areti Angeliki Veroniki^{1,3}, Orestis Efthimiou⁴, Ilkka Kalliala^{1,5},
9 Huseyin Naci⁶, Sarah Lever^{1,2}, Maria Paraskevasidi¹, Pierre Martin-Hirsch⁷, Phillip Bennett^{1,2},
10 Evangelos Paraskevasidis^{2,8}, Georgia Salanti⁴, Maria Kyrgiou^{1,2}
11
12

13
14 ¹Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer,
15 Faculty of Medicine, Imperial College London, UK

16 ²Imperial Healthcare NHS Trust, London, UK

17 ³Department of Primary Education, School of Education, University of Ioannina, Greece

18 ⁴Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg
19 11, 3012 Bern, Switzerland

20 ⁵Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University
21 Hospital, Finland

22 ⁶Department of Health Policy, London School of Economics & Political Science, UK

23 ⁷Department of Gynaecologic Oncology, Lancashire Teaching Hospitals, Preston, UK

24 ⁸Department of Obstetrics & Gynaecology, University of Ioannina and University Hospital of
25 Ioannina, Greece
26
27
28
29

30
31 AA: a.athanasiou@imperial.ac.uk; AAV: a.veroniki@imperial.ac.uk; OE:
32 orestis.efthimiou@ispm.unibe.ch; IK: i.kalliala@imperial.ac.uk; HN: h.naci@lse.ac.uk; SL:
33 s.lever@imperial.ac.uk; MP: m.paraskevasidi@imperial.ac.uk; PMH: pierre.martin-
34 hirsch@lthtr.nhs.uk; PB: p.bennett@imperial.ac.uk; EP: eparaske@cc.uoi.gr; GS:
35 georgia.salanti@ispm.unibe.ch; MK: m.kyrgiou@imperial.ac.uk
36
37
38

39 **Corresponding author:**

40 Maria Kyrgiou, MSc, PhD, MRCOG

41 3rd Floor, IRDB, Department of Surgery & Cancer

42 Imperial College London, Hammersmith Campus

43 Du Cane Road, W12 0NN, London

44 Email: m.kyrgiou@imperial.ac.uk - Tel: +44 2075942177
45
46
47

48 **Word Count:** 3010
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Local treatments for cervical intra-epithelial neoplasia (CIN) and micro-invasive disease remove or ablate a cone-shaped part of the uterine cervix containing the abnormal cells. A trend towards less radical techniques has raised concerns that this may adversely impact the rates of precancerous and cancerous recurrence. However, there has been no strong evidence to support such claims. We hereby describe a protocol of a systematic review and network meta-analysis that will update the evidence and compare all relevant treatments in terms of efficacy and complications.

Methods and Analysis: Literature searches in electronic databases or trial registries will identify published and unpublished randomised controlled trials (RCTs) and cohort studies comparing the efficacy and complications amongst different excisional and ablative techniques. The excisional techniques include cold knife, laser or fischer cone, large loop or needle excision of the transformation zone and the ablative radical point diathermy, cryotherapy, cold coagulation or laser ablation. The primary outcome will be high-grade treatment failure rates, defined as recurrent/residual histologically-proven CIN2 or worse, while secondary outcomes will include treatment failure rates at CIN1+, HPV positivity rates, abnormal cytology and/or histology rates, involved margins rates, and rates of bleeding, inadequate colposcopy and cervical stenosis. We will assess the risk of bias in RCTs and observational studies using tools developed by the Cochrane Collaboration. Two authors will independently assess study eligibility, abstract the data, and assess the risk of bias. Random-effects meta-analyses and network meta-analyses will be conducted using the odds ratio for dichotomous outcomes and the mean difference for continuous outcomes. The quality of the evidence for the primary outcome will be assessed using the CINEMA tool.

Ethics and dissemination: Ethical approval not required. We will disseminate findings to clinicians, policy makers, patients and the public.

PROSPERO registration number: CRD42018115508

ARTICLE SUMMARY

Strengths and limitations of this study

- We plan to conduct the first network meta-analysis to assess the relative efficacy and complication rates of treatment methods for cervical pre-invasive and early micro-invasive disease.
- This study will produce comprehensive summaries of the clinical ranking of treatments and will employ methodologies that will allow the use of both randomised and observational data, aiming to utilise all published evidence.
- The results will inform clinicians, patients and clinical guidelines and will allow effective patient counselling at colposcopy clinics.
- We expect to find retrospective observational studies at high risk of recall, selection and publication bias. We will try overcoming this limitation by employing methods that aim to minimise bias.

KEYWORDS

1
2
3 "Cervical Intraepithelial Neoplasia/surgery"[Mesh]
4 "Cervical Intraepithelial Neoplasia/therapy"[Mesh]
5
6 "Treatment Outcome"[Mesh]
7
8 "Recurrence"[Mesh]
9
10 "Conization/adverse effects"[Mesh]
11
12 "Ablation Techniques/adverse effects"[Mesh]
13

14 INTRODUCTION

15 Organised screening programmes in countries such as the UK, have led to a dramatic
16 decrease in the incidence and mortality from cervical cancer, especially when compared with
17 the corresponding statistics for the other major cancers. Over a twenty-year period, from
18 1993-1995 to 2013-2015, the overall age-standardised incidence rate of cancer in females
19 increased by 16% in the UK¹, whereas the corresponding data for cervical cancer showed a
20 decrease of 24%². Cervical cancer is largely preventable through detection and treatment of
21 the pre-invasive precursor, cervical intra-epithelial neoplasia (CIN)³. The local treatment
22 methods are divided into excisional and destructive (ablative) that aim to remove or ablate
23 respectively a cone shaped part of the cervix that contains the 'transformation zone' with the
24 precancerous cells. Although large loop excision of the transformation zone (LLETZ) is the
25 most commonly used methods in the UK⁴ given its ease of execution and low cost, the
26 preference of techniques varies across Europe and internationally.
27
28
29

30
31 A Cochrane systematic review of RCTs concluded that all local treatment techniques are
32 highly effective in preventing pre-invasive recurrence⁵. However, this review found no
33 evidence of difference in treatment failure rates amongst the treatment techniques. This could
34 be because the RCTs, and the subsequent meta-analysis might have been underpowered to
35 detect differences between the treatments. The largest study recruited only 390 participants⁶,
36 while the majority of the rest were much smaller. A more recent, large, population-based
37 study from Sweden⁷, which included 150,883 women diagnosed and treated for CIN3
38 (3,148,222 woman-years), reported a doubled standardized incidence ratio for post-treatment
39 invasive recurrence during the follow-up period of around 4 decades in comparison to the
40 general population, and initiated debates on the impact that less radical treatments may have
41 on the subsequent risk of invasion⁸. The trend towards techniques that remove smaller parts
42 of the cervix can be attributed to the fact that many of these are easy to do, they are of low
43 cost, and can be performed in an outpatient setting. Increased awareness of the impact of the
44 more radical or deeper techniques on the risk of prematurity may have also contributed⁹⁻²⁰.
45
46
47
48
49

50
51 The impact of different techniques on the risk of pre-invasive and/or invasive recurrence
52 remains therefore unclear. With some advocating the minimum radicality of treatment to
53 prevent treatment-induced reproductive morbidity^{10 21}, and others raising concerns about the
54 increase in the risk of future invasion^{7 8}, a definite answer regarding the relative merits and
55 risks among the various treatment strategies is required.
56
57

58
59 Traditionally, treatment strategies are evaluated via large, expensive trials. Given the possibly
60 comparable and high as well efficacy of most interventions for CIN, it is unlikely that any

1
2
3 adequately powered RCT assessing the relative efficacy of different treatment techniques will
4 ever be conducted. Such a trial would require thousands of women in order to reach the
5 statistical power needed to detect differences in the pre-invasive and invasive recurrence
6 rates. In summary, there is currently a lack of adequately powered randomised evidence to
7 allow us to compare the various interventions. However, there is a plethora of available
8 observational studies in the field. These studies are a potentially valuable source of evidence,
9 and may act as a complement to the available randomised evidence, allowing us to more
10 accurately assess the comparative effectiveness and safety of the various treatment
11 alternatives. In this paper, we aim to perform a systematic review of both randomised and
12 observational studies in the field, and quantitatively synthesize their findings in meta-
13 analyses.
14
15
16
17
18

19 Systematic reviews and pairwise meta-analyses are widely accepted as a useful tool in
20 comparative effectiveness research, and are commonly used to summarise, critically appraise
21 and synthesise evidence from multiple studies. Investigators aiming to address a research
22 question identify all relevant studies, evaluate their quality, synthesise their findings (meta-
23 analysis) and interpret the provided evidence. Systematic reviews and meta-analyses have
24 played a key role in providing evidence on the efficacy and safety of treatment methods and
25 management strategies in cervical cancer prevention. However, the increased number of
26 management strategies and multiple treatment options requires the use of more advanced
27 evidence-synthesis methods.
28
29
30
31

32 Network meta-analysis (NMA) is an extension of pairwise meta-analysis, for the case when
33 multiple treatments are available for the same condition. NMA has been recognised by the
34 National Institute of Clinical Excellence (NICE)²² and several international Health
35 Technology Assessment (HTA) agencies^{23 24} as a methodological tool that has the potential to
36 increase precision in treatment effect estimates but also to infer on the clinical efficacy/
37 safety between treatments that have never been compared in trials. NMA uses both direct
38 evidence (i.e. coming from studies comparing head-to-head the treatments of interest) and
39 indirect evidence (i.e. coming from studies comparing the treatments of interest via an
40 intermediate common comparator)²⁵⁻²⁸, allows the estimation of relative treatment effects
41 between all available interventions, and provides a clinically useful ranking of the different
42 competing treatments. The methodology of NMA has never been used before to assess the
43 comparative efficacy and complications of different treatment techniques used in the
44 management of CIN. Furthermore, novel NMA methodologies will be employed to allow the
45 use of both randomised and observational data.
46
47
48
49
50
51

52 The aim of this systematic review and NMA is to compare and clinically rank the alternative
53 treatment techniques for CIN based on their efficacy, complications and adverse effects. This
54 NMA forms part of the CIRCLE project (Cervical Cancer Incidence, CIN Recurrence and
55 **R**eproduction after **L**ocal **E**xcision), which aims to generate a clinically useful ranking of
56 alternative options for treatment of CIN according to their efficacy (risk of pre-invasive and
57 invasive recurrence), morbidity and cost-effectiveness.
58
59
60

METHODS AND ANALYSIS

This protocol is written in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) (see Supplementary File 1)²⁹.

PROSPERO registration will be updated if we make any amendments to this protocol.

Eligibility criteria of studies

Types of participants

We will include women of all ages treated with local surgical treatment for CIN (or glandular intraepithelial neoplasia) or micro-invasive early cervical cancer (stage IA1). We will only include women with histological diagnosis of CIN.

Types of interventions

The treatment techniques for cervical intraepithelial neoplasia (CIN) are divided into excisional and ablative. The excisional include cold knife conisation (CKC), laser conisation (LC), needle excision of the transformation zone (NETZ), also known as straight wire excision of the transformation zone (SWETZ), large loop excision of the transformation zone (LLETZ), also known as loop electrosurgical excisional procedure (LEEP) and Fischer cone biopsy excisor (FCBE), while the ablative include radical point diathermy (RD), cryotherapy (CT), cold coagulation (CC) and laser ablation (LA). Figure 1 displays a network example of comparisons between studied treatment techniques. When the treatment is not specified, we will group these under wider categories excision (ENS) or ablation (ANS).

Outcome measures

Primary outcome

- High-grade treatment failure rates defined as recurrent or residual histologically-proven CIN2 or worse

Secondary outcomes

- Treatment failure rates defined as histologically-proven CIN1 or worse
- Abnormal cytology (defined as ASCUS or worse) and/or histology CIN1 or worse
- HPV positivity rates
- Involved margins rates (endocervical, ectocervical, or both)
- Peri-operative or post-operative bleeding
- Cervical stenosis

Primary and secondary outcomes were chosen by clinical experts of the team.

Types of studies

We will include RCTs, quasi-RCTs and observational cohort studies comparing rates of treatment failure (recurrent/residual disease) or complications amongst the abovementioned surgical techniques. Single-arm studies not presenting a comparison will be excluded. Studies will be considered regardless of time or language.

Information sources and search strategy

The Cochrane Gynaecological Cancer Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE will be searched for eligible studies by an experienced librarian, as presented in Supplementary File 2. Metaregister, Physicians Data Query, www.controlled-trials.com/rct, www.clinicaltrials.gov and www.cancer.gov/clinicaltrials will be searched for ongoing studies. ZETOC (<http://zetoc.mimas.ac.uk>) and WorldCat Dissertations will be searched for conference proceedings and theses, respectively. References of the retrieved articles and meta-analyses will be hand-searched, the “related articles” feature in MEDLINE will be employed and experts in the field will be contacted in an attempt to identify further reports of studies. Corresponding authors will be contacted for any relevant ongoing trials and unpublished data.

We will include both published and unpublished data and there will be no time, place or language restriction.

Study selection

Two team members will independently screen titles and abstracts of citations at level 1, using the reference management software Zotero. At level 2, the full text of all potentially eligible articles will be assessed using the same inclusion criteria. Disagreements will be resolved through discussion with a third review author.

Data collection

Data from the included studies will be abstracted at level 3 by two reviewers independently using an a priori developed data collection form in Excel. The following data will be abstracted from the included studies: study characteristics, including author, publication year study design, inclusion/exclusion criteria, and intervention details, participant characteristics, including age, CIN grade and smoking, and dropout rates, and outcome characteristics. In RCTs, we will prefer arm-level data (number of events and sample size per intervention arm for dichotomous data, and mean and standard deviation (SD) per intervention arm for continuous data), but if these are missing, the study-level data will be used in the analysis, e.g. reported odds ratios (ORs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, along with a measure of uncertainty (e.g., confidence interval [CI]). For continuous outcome data not reported as means and standard deviations, we will first contact the corresponding study authors for further information, but if no additional data are provided, we will perform imputation methods to derive approximate effect measures^{30 31}. When an eligible study is observational, we will prefer adjusted treatment effect estimates accounting for the impact of potential confounders, but if these are missing, the unadjusted estimated treatment effects will be abstracted with a corresponding uncertainty measure (e.g. CI). Disagreements will be resolved through consensus or the involvement of a third reviewer.

Risk of bias assessment

RCTs will be assessed for quality and risk of bias using the Cochrane risk of bias tool³² in the following domains: randomisation process, deviations from the intended interventions,

1
2
3 missing outcome data, measurement of the outcome and selection of the reported result. The
4 risk of bias in each domain, as well as the overall risk of bias, will be rated as “low risk”,
5 “some concerns”, or “high risk”, after answering the signalling questions of each domain
6 with “Yes”, “Potentially Yes”, “Potentially No” or “No”. Non-randomised studies (NRS) will
7 be assessed using the ROBINS-I tool³³ with potential confounding factors: grade of treated
8 CIN, age and smoking. The following domains will be assessed for NRS: confounding,
9 selection of participants into the study, classification of interventions, deviations from
10 intended interventions, missing data, measurement of outcomes and selection of the reported
11 results. The risk of bias in each domain, as well as the overall risk of bias, will be rated as
12 “low”, “moderate”, “serious”, or “critical”, after answering the signalling questions of each
13 domain with “Yes”, “Potentially Yes”, “Potentially No” or “No”. Pairs of team members will
14 independently assess the methodological quality and risk of bias of the eligible studies.
15 Conflicts will be resolved through discussion or with a third investigator. When inadequate
16 information is available from the studies to rate a risk of bias item, we will contact the
17 corresponding study authors for clarification.
18
19
20
21
22
23

24 **Statistical synthesis**

25 Characteristics of included studies and Network

26 For each outcome, we will produce a network plot (see for example Figure 1) of the available
27 evidence, as well as descriptive statistics, including comparison type, publication year, study
28 design, outcome data, and potential effect modifiers (e.g., age).
29
30
31

32 Pairwise Meta-analyses

33 A random-effects meta-analysis will be conducted for each pairwise comparison in each
34 outcome using the inverse variance model and the the Hartung-Knapp-Sidik-Jonkman
35 method to estimate each summary treatment effect and its 95% CI³⁴⁻³⁶. The between-study
36 variance will be estimated with the restricted maximum likelihood estimator, whereas its 95%
37 CI with the Q-profile approach^{34 37 38}. We will also use the I^2 statistic along a 95% CI^{39 40} to
38 evaluate between-study heterogeneity. For continuous outcomes we will report the summary
39 MDs, whereas for dichotomous outcomes we will use the summary ORs, along with a 95%
40 CI. The *metafor* package⁴¹ in R⁴² will be used for all meta-analyses.
41
42
43
44

45 Network meta-analyses (NMA)

46 *Data synthesis*

47 A random-effects NMA will be conducted, since we anticipate methodological and clinical
48 between-study heterogeneity. We will assume common between-study variance parameter
49 across treatment comparisons in the network, so that comparisons informed by a single study
50 can borrow strength from the remaining network^{43 44}. This assumption is clinically
51 reasonable because all treatments included in the network of trials are of the same nature. The
52 between-study variance will be estimated with the DerSimonian and Laird method of
53 moments approach⁴⁵. We will employ the design-adjusted⁴⁶ and a three-level hierarchical
54 NMA models as described in Efthimiou et al⁴⁶ by incorporating all the available information,
55 both RCTs and NRS, in a single NMA model. We will explore the impact of assigning
56
57
58
59
60

1
2
3 different levels of credibility and subsequently down-weighting the NRS according to
4 experts' opinion and the results of the ROBINS-I tool in several sensitivity analyses.
5
6

7 Similar to the pairwise meta-analysis, for continuous outcomes we will report the estimated
8 MDs, whereas for dichotomous outcomes we will use the estimated ORs, with a 95% CI.
9 Along the 95% CI for the summary effect size, we will report 95% prediction intervals to
10 observe the interval within which the effect estimate is expected to lie should another trial
11 become available⁴⁷. To rank the efficacy for each intervention, we will calculate the ranking
12 probabilities for all treatments, the surface under the cumulative ranking curve (SUCRA) or
13 P-scores, and the mean ranks^{48 49}. A rank-heat plot will be used to depict the SUCRA values
14 or P-scores across all outcomes⁵⁰. We will apply all NMA models in R⁴² using the *netmeta*
15 package⁵¹ and *rjags*⁵² package..
16
17
18
19

20 *Assessment of the transitivity assumption*

21 One of the prerequisite assumptions in NMA is the transitivity assumption, under which the
22 effect modifiers have a similar distribution across treatment comparisons in a network^{27 53 54}.
23 Potential effect modifiers expected to influence the estimated treatment effects include year
24 of study, method of ascertainment of exposure/outcome (hospital records, registries or
25 interviews/questionnaires), age, smoking and grade of CIN. For each pairwise comparison
26 with available direct evidence we will summarize these characteristics and will visually
27 inspect the similarity of the identified studies. We will also investigate the inclusion and
28 exclusion criteria of all studies, to make sure that patients, treatments and outcomes in the
29 studies are sufficiently similar in all aspects that might modify relative treatment effects.
30
31
32
33
34

35 *Assessment of statistical inconsistency*

36 Consistency in a network of trials will be evaluated both locally and globally. We will first
37 assess the consistency assumption locally by separating the direct from the indirect evidence
38 for every comparison in a network to make judgements about their statistical differences,
39 using the back-calculation method⁵⁵. Then we will assess consistency in each network
40 globally using the design-by-treatment interaction model⁵⁶. We will conceptually explore for
41 potential intransitivity in every network even in the absence of evidence for inconsistency,
42 since the inconsistency tests have low power to detect true inconsistency^{57 58}. If no substantial
43 inconsistency is identified in the network of RCTs, we will then evaluate the agreement
44 between RCTs and NRS using the same local and global approaches. Both local (back-
45 calculation method) and global (design-by-treatment interaction model) assessments will be
46 performed under the random-effects model in R⁴² using the *netmeta* package⁵¹.
47
48
49
50
51

52 In the NMA including both RCTs and NRS, we will assess for differences between the
53 different study designs⁴⁶. For each treatment comparison we will summarize evidence by up
54 to four different types: direct randomised, indirect randomised, direct non-randomised and
55 indirect non-randomised. If important discrepancies between these types are found, these will
56 be investigated to confirm that the transitivity assumption holds (e.g. when randomised and
57 non-randomised evidence are very different in terms of populations, interventions, etc., the
58
59
60

transitivity assumption may be violated). If disagreement occurs for a certain characteristic, this will be explored through a network meta-regression model²⁶.

Exploring heterogeneity and inconsistency: subgroup analyses and meta-regression

The between-study heterogeneity will be explored by comparing the estimated between-study variance with the empirical distribution derived by Rhodes et al for continuous data⁵⁹ and the one derived by Turner et al for dichotomous data⁶⁰. We will also compare 95% CIs with the 95% prediction intervals to infer on the magnitude of the between-study variance.

If at least 10 studies are available, the following potential sources of heterogeneity and/or inconsistency will be explored for the primary outcome using subgroup or meta-regression analyses: year of study, method of ascertainment of exposure/outcome (hospital records, registries or interviews/questionnaires), age, smoking and grade of CIN.

Reporting bias and small study effects

We will assess small-study effects by visually exploring the funnel-plot for each treatment, and the comparison adjusted funnel plot⁶¹ when at least 10 studies are available. We will also conduct a network meta-regression using the study variance as a covariate^{62 63}.

Assessment of the credibility of the evidence

For the primary outcome, two team members will determine the degree of confidence in the estimated NMA results using CINEMA⁶⁴ and the relevant online tool (<http://cinema.ispm.ch/>). The six CINEMA domains, within-study bias (i.e., risk of bias in the included studies), across-study bias (i.e., publication and reporting bias), indirectness, imprecision, heterogeneity and incoherence (i.e., differences between direct and indirect evidence)⁶⁴, will first be rated as high quality, and then they will be downgraded if judged appropriate to moderate, low, or very low quality.

ETHICS AND DISSEMINATION

We do not require ethical approval for this review. We aim to disseminate the results to clinicians, academic researchers, health agencies and decision makers, to patients and the public. We will publish the results in high impact open access journals and disseminate findings through presentations at medical conferences. The data will become available in public repositories. We will develop information sheets and briefings, highlighting the key findings and circulate newsletters. We will work closely with the Jo's Trust, charity in cervical cancer that frequently organises events to educate the public and also engage the media with interviews. We circulate findings in the Imperial College webpage and will circulate newsletters.

Figure 1. Network of possible pairwise comparisons between eligible treatment methods
Abbreviations: **FCBE**=Fischer cone biopsy excision; **LLETZ**= large loop excision of the transformation zone, also known as **LEEP**=loop electrosurgical excisional procedure; **NETZ**=needle excision of the transformation, also known as **SWETZ**=straight wire excision

of the transformation zone; **LC**=laser conisation; **CKC**=cold knife conisation; **LA**=laser ablation; **CC**=cold coagulation; **CT**=cryotherapy; **RD**=radical point diathermy

REFERENCES

1. CancerResearchUK. Cancer incidence for all cancers combined 2018 [Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/all-cancers-combined>].
2. CancerResearchUK. Cervical cancer incidence statistics 2018 [Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer/incidence>].
3. Scarinci IC, Garcia FA, Kobetz E, et al. Cervical cancer prevention: new tools and old barriers. *Cancer* 2010;116(11):2531-42. doi: 10.1002/cncr.25065 [published Online First: 2010/03/24]
4. NHS. Colposcopy: Treatments 2017 [Available from: <https://www.nhs.uk/conditions/colposcopy/treatment/>].
5. Martin-Hirsch PP, Paraskeva E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. *Cochrane Database Syst Rev* 2013(12):Cd001318. doi: 10.1002/14651858.CD001318.pub3 [published Online First: 2013/12/05]
6. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. *Obstetrics and gynecology CNO - CN-00156163* 1998;92(5 XMAN - MEDLINE 1999008792 XMO - SU XSR - SR-GYNAECA):737-44.
7. Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. *BMJ* 2014;348:f7361. [published Online First: 2014/01/14]
8. Arbyn M, Kyrgiou M, Gondry J, et al. Long term outcomes for women treated for cervical precancer. *Bmj* 2014;348:f7700. doi: 10.1136/bmj.f7700 [published Online First: 2014/01/16]
9. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. *Lancet* 2006;367(9509):489-98. doi: 10.1016/s0140-6736(06)68181-6 [published Online First: 2006/02/14]
10. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. *Bmj* 2008;337:a1284. doi: 10.1136/bmj.a1284 [published Online First: 2008/09/20]
11. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. *Bmj* 2014;349:g6192. doi: 10.1136/bmj.g6192 [published Online First: 2014/10/30]
12. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. *Cochrane Database Syst*

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Rev 2015(9):Cd008478. doi: 10.1002/14651858.CD008478.pub2 [published Online First: 2015/09/30]
13. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. *Bmj* 2016;354:i3633. doi: 10.1136/bmj.i3633 [published Online First: 2016/07/30]
14. Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. *Cochrane Database Syst Rev* 2017;11:CD012847. doi: 10.1002/14651858.Cd012847 [published Online First: 2017/11/03]
15. Kyrgiou M, Arbyn M, Martin-Hirsch P, et al. Increased risk of preterm birth after treatment for CIN. *Bmj* 2012;345:e5847. doi: 10.1136/bmj.e5847 [published Online First: 2012/09/07]
16. Castanon A, Landy R, Brocklehurst P, et al. Risk of preterm delivery with increasing depth of excision for cervical intraepithelial neoplasia in England: nested case-control study. *BMJ* 2014;349:g6223. [published Online First: 2014/11/05]
17. Noehr B, Jensen A, Frederiksen K, et al. Depth of cervical cone removed by loop electrosurgical excision procedure and subsequent risk of spontaneous preterm delivery. *Obstet Gynecol* 2009;114(6):1232-8. doi: 10.1097/AOG.0b013e3181bf1ef2 [published Online First: 2009/11/26]
18. Khalid S, Dimitriou E, Conroy R, et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. *Bjog* 2012;119(6):685-91. doi: 10.1111/j.1471-0528.2011.03252.x [published Online First: 2012/02/15]
19. Founta C, Arbyn M, Valasoulis G, et al. Proportion of excision and cervical healing after large loop excision of the transformation zone for cervical intraepithelial neoplasia. *Bjog* 2010;117(12):1468-74. doi: 10.1111/j.1471-0528.2010.02709.x [published Online First: 2010/09/16]
20. Kyrgiou M, Valasoulis G, Stasinou SM, et al. Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. *Int J Gynaecol Obstet* 2015;128(2):141-7. doi: 10.1016/j.ijgo.2014.07.038 [published Online First: 2014/12/03]
21. Paraskevaidis E, Kyrgiou M, Martin-Hirsch P. Have we dismissed ablative treatment too soon in colposcopy practice? *Bjog* 2007;114(1):3-4. doi: 10.1111/j.1471-0528.2006.01178.x [published Online First: 2007/01/20]
22. NICE. Developing NICE guidelines: the manual. Process and methods (PMG20). Reviewing research evidence 2017 [Available from: <https://www.nice.org.uk/process/pmg20/chapter/reviewing-research-evidence>].
23. Caldwell DM, Dias S, Welton NJ. Extending Treatment Networks in Health Technology Assessment: How Far Should We Go? *Value Health* 2015;18(5):673-81. doi: 10.1016/j.jval.2015.03.1792 [published Online First: 2015/08/25]
24. CADTH. Network Meta-Analysis 2015 [Available from: <https://www.cadth.ca/network-meta-analysis>].

- 1
- 2
- 3
- 4 25. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments:
5 combining direct and indirect evidence. *BMJ* 2005;331(7521):897-900. doi:
6 10.1136/bmj.331.7521.897
- 7
- 8 26. Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis
9 demonstrates that covariates should be considered. *J Clin Epidemiol* 2009;62(8):857-
10 64. doi: 10.1016/j.jclinepi.2008.10.001 [published Online First: 2009/01/20]
- 11
- 12 27. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network
13 meta-analysis. *Ann Intern Med* 2013;159(2):130-7. doi: 10.7326/0003-4819-159-2-
14 201307160-00008
- 15
- 16 28. Efthimiou O, Debray TP, van Valkenhoef G, et al. GetReal in network meta-analysis: a
17 review of the methodology. *Res Synth Methods* 2016;7(3):236-63. doi:
18 10.1002/jrsm.1195 [published Online First: 2016/01/13]
- 19
- 20 29. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review
21 and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi:
22 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
- 23
- 24 30. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-
25 analyses can provide accurate results. *J Clin Epidemiol* 2006;59(1):7-10. doi:
26 10.1016/j.jclinepi.2005.06.006 [published Online First: 2005/12/20]
- 27
- 28 31. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for
29 assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. doi:
30 10.1136/bmj.d5928 [published Online First: 2011/10/20]
- 31
- 32 32. Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in
33 randomized trials. In: Chandler J, McKenzie J, Boutron I, et al., eds.: *Cochrane*
34 *Methods*. Cochrane Database of Systematic Reviews 2016.
- 35
- 36 33. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in
37 non-randomised studies of interventions. *BMJ* 2016;355:i4919. doi:
38 10.1136/bmj.i4919 [published Online First: 2016/10/14]
- 39
- 40 34. Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study
41 variance and its uncertainty in meta-analysis. *Res Synth Methods* 2016;7(1):55-79.
42 doi: 10.1002/jrsm.1164 [published Online First: 2015/09/04]
- 43
- 44 35. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials
45 with binary outcome. *Stat Med* 2001;20(24):3875-89. [published Online First:
46 2002/01/10]
- 47
- 48 36. Sidik K, Jonkman JN. A simple confidence interval for meta-analysis. *Stat Med*
49 2002;21(21):3153-9. doi: 10.1002/sim.1262 [published Online First: 2002/10/11]
- 50
- 51 37. Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance
52 estimators in simulated random-effects meta-analyses. *Res Synth Methods* 2018 doi:
53 10.1002/jrsm.1316 [published Online First: 2018/08/02]
- 54
- 55 38. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis.
56 *Stat Med* 2007;26(1):37-52. doi: 10.1002/sim.2514 [published Online First:
57 2006/02/08]
- 58
- 59 39. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.
60 *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online
First: 2003/09/06]

- 1
- 2
- 3
- 4 40. Veroniki AA, Jackson D, Viechtbauer W, et al. Recommendations for quantifying the
- 5 uncertainty in the summary intervention effect and estimating the between-study
- 6 heterogeneity variance in random-effects meta-analysis. In: Chandler J, McKenzie J,
- 7 Boutron I, et al., eds.: *Cochrane Methods*. Cochrane Database of Systematic Reviews
- 8 2015.
- 9
- 10 41. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package.
- 11 2010;36(3):48.
- 12
- 13 42. RDevelopmentCoreTeam. R: A language and environment for statistical computing.
- 14 Vienna, Austria: R Foundation for Statistical Computing, 2013.
- 15 43. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. *Stat*
- 16 *Methods Med Res* 2008;17(3):279-301. doi: 10.1177/0962280207080643 [published
- 17 Online First: 2007/10/09]
- 18
- 19 44. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. *Stat*
- 20 *Med* 1996;15(24):2733-49. doi: 10.1002/(SICI)1097-
- 21 0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0
- 22
- 23 45. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity
- 24 in multivariate meta-analyses. *Stat Med* 2012;31(29):3805-20. doi: 10.1002/sim.5453
- 25 [published Online First: 2012/07/06]
- 26
- 27 46. Efthimiou O, Mavridis D, Debray TP, et al. Combining randomized and non-randomized
- 28 evidence in network meta-analysis. *Stat Med* 2017;36(8):1210-26. doi:
- 29 10.1002/sim.7223 [published Online First: 2017/01/14]
- 30
- 31 47. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*
- 32 2011;342:d549. doi: 10.1136/bmj.d549 [published Online First: 2011/02/12]
- 33
- 34 48. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for
- 35 presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J*
- 36 *Clin Epidemiol* 2011;64(2):163-71. doi: 10.1016/j.jclinepi.2010.03.016 [published
- 37 Online First: 2010/08/05]
- 38
- 39 49. Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works
- 40 without resampling methods. *BMC medical research methodology* 2015;15:58. doi:
- 41 10.1186/s12874-015-0060-8 [published Online First: 2015/08/01]
- 42
- 43 50. Veroniki AA, Straus SE, Fyraridis A, et al. The rank-heat plot is a novel way to present
- 44 the results from a network meta-analysis including multiple outcomes. *J Clin*
- 45 *Epidemiol* 2016;76:193-9. doi: 10.1016/j.jclinepi.2016.02.016 [published Online
- 46 First: 2016/03/05]
- 47
- 48 51. Rucker G, Schwarzer G, Krahn U, et al. netmeta: Network Meta-Analysis using
- 49 Frequentist Methods. R package version 0.9-8. 2018 [Available from:
- 50 <https://CRAN.R-project.org/package=netmeta>.
- 51
- 52 52. Plummer M. rjags: Bayesian Graphical Models using MCMC. R package version 4-8
- 53 2018 [Available from: <https://CRAN.R-project.org/package=rjags>.
- 54
- 55 53. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments
- 56 meta-analysis: many names, many benefits, many concerns for the next generation
- 57 evidence synthesis tool. *Res Synth Methods* 2012;3(2):80-97. doi: 10.1002/jrsm.1037
- 58 [published Online First: 2012/06/11]
- 59
- 60

- 1
2
3 54. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis?
4 It all depends on the distribution of effect modifiers. *BMC Med* 2013;11:159. doi:
5 10.1186/1741-7015-11-159 [published Online First: 2013/07/04]
6
7 55. Konig J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis
8 and characterizing mixed treatment comparisons. *Stat Med* 2013;32(30):5414-29. doi:
9 10.1002/sim.6001 [published Online First: 2013/10/15]
10
11 56. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-
12 analysis: model estimation using multivariate meta-regression. *Res Synth Methods*
13 2012;3(2):111-25. doi: 10.1002/jrsm.1045
14
15 57. Veroniki AA, Mavridis D, Higgins JP, et al. Characteristics of a loop of evidence that
16 affect detection and estimation of inconsistency: a simulation study. *BMC medical*
17 *research methodology* 2014;14:106. doi: 10.1186/1471-2288-14-106 [published
18 Online First: 2014/09/23]
19
20 58. Song F, Clark A, Bachmann MO, et al. Simulation evaluation of statistical properties of
21 methods for indirect and mixed treatment comparisons. *BMC medical research*
22 *methodology* 2012;12:138. doi: 10.1186/1471-2288-12-138 [published Online First:
23 2012/09/14]
24
25 59. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the
26 extent of heterogeneity in meta-analyses of continuous outcome data. *J Clin*
27 *Epidemiol* 2015;68(1):52-60. doi: 10.1016/j.jclinepi.2014.08.012 [published Online
28 First: 2014/10/12]
29
30 60. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-
31 analysis, using empirical data from the Cochrane Database of Systematic Reviews. *Int*
32 *J Epidemiol* 2012;41(3):818-27. doi: 10.1093/ije/dys041 [published Online First:
33 2012/03/31]
34
35 61. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in
36 STATA. *PLoS One* 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654
37 [published Online First: 2013/10/08]
38
39 62. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-
40 study effects in a network of interventions. *Res Synth Methods* 2012;3(2):161-76. doi:
41 10.1002/jrsm.57 [published Online First: 2012/06/01]
42
43 63. Mavridis D, Efthimiou O, Leucht S, et al. Publication bias and small-study effects
44 magnified effectiveness of antipsychotics but their relative ranking remained
45 invariant. *J Clin Epidemiol* 2016;69:161-9. doi: 10.1016/j.jclinepi.2015.05.027
46 [published Online First: 2015/07/27]
47
48 64. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a
49 network meta-analysis. *PLoS One* 2014;9(7):e99682. doi:
50 10.1371/journal.pone.0099682 [published Online First: 2014/07/06]
51
52
53

54 STATEMENTS

57 Declaration

58 The corresponding author had full access to all the data in the study and the final
59 responsibility for the decision to submit for publication.
60

1
2
3 The senior author MK (the manuscript's guarantor) affirms that the manuscript is an honest,
4 accurate, and transparent account of the study being reported and that no important aspects of
5 the study have been omitted.
6
7

8 **Author statement**

9
10 The study was conceived and designed by MK, GS and EP. The protocol was drafted by AA,
11 MK, AAV, OE, IK, GS and was revised critically for important intellectual content by all
12 authors (AA, AAV, OE, IK, HN, SL, MP, PMH, PB, EP, GS, MK).
13
14

15 **Acknowledgements**

16 All contributors are listed as authors.
17
18

19 **Funding statement**

20 This work is supported by National Institute for Health Research (NIHR) Research for
21 Patient Benefits (P67307)(MK). It is also supported by the British Society of Colposcopy
22 Cervical Pathology Jordan/Singer Award (P47773) and the Imperial College Healthcare
23 Charity (P47907)(MK). AAV is funded by the European Union's Horizon 2020 (No 754936).
24 None of the funders have any influence on the study design; in the collection, analysis, and
25 interpretation of data; in the writing of the report; and in the decision to submit the article for
26 publication.
27
28
29
30

31 **Competing interests statement**

32 We have read and understood BMJ policy on declaration of interests and declare that we have
33 no conflict of interests. All authors have completed the ICMJE uniform disclosure form at
34 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
35 submitted work; no financial relationships with any organisations that might have an interest
36 in the submitted work in the previous three years; no other relationships or activities that
37 could appear to have influenced the submitted work.
38
39

40 Dr Kyrgiou has received travel and conference expenses, honoraria and consultancy fees for
41 commercial companies (Inovio, MSD etc); these activities are not related to the project.
42
43

44 **Data sharing**


45 No additional data available.
46
47

48 **Copyright statement**

49 "The Corresponding Author has the right to grant on behalf of all authors and does grant on
50 behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in
51 all forms, formats and media (whether known now or created in the future), to i) publish,
52 reproduce, distribute, display and store the Contribution, ii) translate the Contribution into
53 other languages, create adaptations, reprints, include within collections and create summaries,
54 extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on
55 the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of
56 electronic links from the Contribution to third party material where-ever it may be located;
57 and, vi) licence any third party to do any or all of the above."
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



Network of possible pairwise comparisons between eligible treatment methods

235x142mm (72 x 72 DPI)

Supplementary File 1: Reporting checklist for protocol of a systematic review

Based on the PRISMA-P guidelines.

		Reporting Item	Page Number
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	N/A (no previous NMA)
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	14
	#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	4
Sources	#5a	Indicate sources of financial or other support for the review	15
Sponsor	#5b	Provide name for the review funder and / or sponsor	15
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	15
Rationale	#6	Describe the rationale for the review in the context of what is already known	3-4
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5

1	Information	#9	Describe all intended information sources (such as electronic	5-6
2	sources		databases, contact with study authors, trial registers or other	
3			grey literature sources) with planned dates of coverage	
4				
5				
6	Search strategy	#10	Present draft of search strategy to be used for at least one	5;
7			electronic database, including planned limits, such that it could	Supplementary
8			be repeated	File 2
9				
10				
11	Study records -	#11a	Describe the mechanism(s) that will be used to manage records	6
12	data management		and data throughout the review	
13				
14				
15	Study records -	#11b	State the process that will be used for selecting studies (such as	6
16	selection process		two independent reviewers) through each phase of the review	
17			(that is, screening, eligibility and inclusion in meta-analysis)	
18				
19				
20				
21	Study records -	#11c	Describe planned method of extracting data from reports (such	6
22	data collection		as piloting forms, done independently, in duplicate), any	
23	process		processes for obtaining and confirming data from investigators	
24				
25				
26	Data items	#12	List and define all variables for which data will be sought (such	6
27			as PICO items, funding sources), any pre-planned data	
28			assumptions and simplifications	
29				
30				
31	Outcomes and	#13	List and define all outcomes for which data will be sought,	5
32	prioritization		including prioritization of main and additional outcomes, with	
33			rationale	
34				
35				
36				
37	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	6-7
38	individual studies		individual studies, including whether this will be done at the	
39			outcome or study level, or both; state how this information will	
40			be used in data synthesis	
41				
42				
43	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	7
44			synthesised	
45				
46				
47		#15b	If data are appropriate for quantitative synthesis, describe	7-8
48			planned summary measures, methods of handling data and	
49			methods of combining data from studies, including any planned	
50			exploration of consistency (such as I ² , Kendall's τ)	
51				
52				
53				
54		#15c	Describe any proposed additional analyses (such as sensitivity	8-9
55			or subgroup analyses, meta-regression)	
56				
57				
58		#15d	If quantitative synthesis is not appropriate, describe the type of	N/A
59				
60				

summary planned

1				
2				
3	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	9
4			publication bias across studies, selective reporting within	
5			studies)	
6				
7				
8	Confidence in	#17	Describe how the strength of the body of evidence will be	9
9	cumulative		assessed (such as GRADE)	
10	evidence			
11				
12				

13 The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY
14 4.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR](#)
15 [Network](#) in collaboration with [Penelope.ai](#)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary File 2: Search algorithms

Medline Ovid RCT only

- 1 exp Cervical Intraepithelial Neoplasia/
- 2 CIN.mp.
- 3 (cervi* and (intraepithel* or epithel*)).mp.
- 4 (cervi* and dysplasia).mp.
- 5 (cervi* and carcinoma in situ).mp.
- 6 (cervi* and cancer in situ).mp.
- 7 (cervi* and (precancer* or pre-cancer*)).mp.
- 8 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9 surgery.fs.
- 10 exp Gynecologic Surgical Procedures/
- 11 (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
- 12 or transformation zone or LLETZ or LEEP).mp.
- 13 9 or 10 or 11
- 14 8 and 12
- 15 randomized controlled trial.pt.
- 16 controlled clinical trial.pt.
- 17 randomized.ab.
- 18 placebo.ab.
- 19 clinical trials as topic.sh.
- 20 randomly.ab.
- 21 trial.ti.
- 22 14 or 15 or 16 or 17 or 18 or 19 or 20
- 23 13 and 21

Medline Ovid NON RCT only

1. exp Cervical Intraepithelial Neoplasia/
2. CIN.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
3. (cervi* and (intraepithel* or epithel*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
4. (cervi* and dysplasia).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

- 1
- 2
- 3
- 4 5. (cervi* and carcinoma in situ).mp. [mp=title, abstract, original title, name of
- 5 substance word, subject heading word, keyword heading word, protocol
- 6 supplementary concept word, rare disease supplementary concept word, unique
- 7 identifier, synonyms]
- 8
- 9 6. (cervi* and cancer in situ).mp. [mp=title, abstract, original title, name of substance
- 10 word, subject heading word, keyword heading word, protocol supplementary concept
- 11 word, rare disease supplementary concept word, unique identifier, synonyms]
- 12
- 13 7. (cervi* and (precancer* or pre-cancer*)).mp. [mp=title, abstract, original title,
- 14 name of substance word, subject heading word, keyword heading word, protocol
- 15 supplementary concept word, rare disease supplementary concept word, unique
- 16 identifier, synonyms]
- 17
- 18 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 19
- 20 9. surgery.fs.
- 21
- 22
- 23 10. exp Gynecologic Surgical Procedures/
- 24
- 25 11. (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
- 26 or transformation zone or LLETZ or LEEP).mp. [mp=title, abstract, original title,
- 27 name of substance word, subject heading word, keyword heading word, protocol
- 28 supplementary concept word, rare disease supplementary concept word, unique
- 29 identifier, synonyms]
- 30
- 31 12. 9 or 10 or 11
- 32
- 33 13. 8 and 12
- 34
- 35 14. randomized controlled trial.pt.
- 36
- 37 15. controlled clinical trial.pt.
- 38
- 39 16. randomized.ab.
- 40
- 41 17. placebo.ab.
- 42
- 43 18. clinical trials as topic.sh.
- 44
- 45 19. randomly.ab.
- 46
- 47 20. trial.ti.
- 48
- 49 21. groups.ab.
- 50
- 51 22. exp cohort studies/
- 52
- 53 23. exp case-control studies/
- 54
- 55 24. (cohort* or prospective* or retrospective* or (case* and (control* or series))).mp.
- 56
- 57 25. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
- 58
- 59 26. (animals not (humans and animals)).sh.
- 60
27. 25 not 26
28. 13 and 27

Embase Ovid RCT only

- 1 exp Uterine Cervix Carcinoma in Situ/

- 1
2
3
4 2 CIN.mp.
5 3 (cervi* and (intraepithel* or epithel*)).mp.
6 4 (cervi* and dysplasia).mp.
7 5 (cervi* and carcinoma in situ).mp.
8 6 (cervi* and cancer in situ).mp.
9 7 (cervi* and (precancer* or pre-cancer*)).mp.
10 8 1 or 2 or 3 or 4 or 5 or 6 or 7
11 9 su.fs.
12 10 exp gynecologic surgery/
13 11 (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
14 or transformation zone or LLETZ or LEEP).mp.
15 12 9 or 10 or 11
16 13 8 and 12
17 14 crossover procedure/
18 15 double-blind procedure/
19 16 randomized controlled trial/
20 17 single-blind procedure/
21 18 random*.mp.
22 19 factorial*.mp.
23 20 (crossover* or cross over* or cross-over*).mp.
24 21 placebo*.mp.
25 22 (double* adj blind*).mp.
26 23 (singl* adj blind*).mp.
27 24 assign*.mp.
28 25 allocat*.mp.
29 26 volunteer*.mp.
30 27 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
31 28 13 and 27

Embase Ovid All Studies

1. exp Uterine Cervix Carcinoma in Situ/
2. CIN.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
3. (cervi* and (intraepithel* or epithel*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]

4. (cervi* and dysplasia).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
5. (cervi* and carcinoma in situ).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
6. (cervi* and cancer in situ).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
7. (cervi* and (precancer* or pre-cancer*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. su.fs.
10. exp gynecologic surgery/
11. (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy or transformation zone or LLETZ or LEEP).mp.
12. 9 or 10 or 11
13. 8 and 12
14. exp controlled clinical trial/
15. randomized.ab.
16. randomly.ab.
17. trial.ab.
18. groups.ab.
19. exp cohort analysis/
20. cohort*.mp.
21. exp retrospective study/
22. exp prospective study/
23. (case* and series).mp.
24. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
25. 13 and 24

CENTRAL

- #1 MeSH descriptor Cervical Intraepithelial Neoplasia explode all trees
- #2 CIN
- #3 cervi* and (intraepithel* or epithel*)
- #4 cervi* and dysplasia
- #5 cervi* and carcinoma in situ
- #6 cervi* and cancer in situ
- #7 cervi* and (precancer* or pre-cancer*)
- #8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)

1
2
3 #9 Any MeSH descriptor with qualifier(s): [Surgery - SU]
4 #10 MeSH descriptor: [Gynecologic Surgical Procedures] explode all trees
5 #11 surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
6 or transformation zone or LLETZ or LEEP
7
8 #12 #9 or #10 or #11
9 #13 #8 and #12
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open

Comparative efficacy and complication rates after local treatment for cervical intra-epithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-028008.R1
Article Type:	Protocol
Date Submitted by the Author:	07-Jun-2019
Complete List of Authors:	<p>Athanasiou, Antonios; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p> <p>Veroniki, Areti Angeliki; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Panepistimio Ioanninon, School of Education, Department of Primary Education</p> <p>Efthimiou, Orestis; University of Bern, Institute of Social and Preventive Medicine (ISPM)</p> <p>Kalliala, Ilkka; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; University of Helsinki and Helsinki University Hospital, Department of Obstetrics and Gynaecology</p> <p>Naci, Huseyin; London School of Economics, Department of Health Policy</p> <p>Lever, Sarah; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p> <p>Paraskevaidi, Maria; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London</p> <p>Martin-Hirsch, Pierre; Lancashire Teaching Hospitals NHS Foundation Trust, Department of Gynaecologic Oncology</p> <p>Bennett, Philip; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p> <p>Paraskevaidis, Evangelos; University of Ioannina and University Hospital of Ioannina, Department of Obstetrics & Gynaecology; Imperial College Healthcare NHS Trust</p> <p>Salanti, Georgia; University of Bern, Institute of Social and Preventive Medicine (ISPM)</p> <p>Kyrgiou, Maria; Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer, Faculty of Medicine, Imperial College London; Imperial College Healthcare NHS Trust</p>
Primary Subject Heading:	Obstetrics and gynaecology
Secondary Subject Heading:	Evidence based practice

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Keywords:	"Cervical Intraepithelial Neoplasia/surgery"[Mesh], "Cervical Intraepithelial Neoplasia/therapy"[Mesh], "Treatment Outcome"[Mesh], "Recurrence"[Mesh], "Conization/adverse effects"[Mesh], "Ablation Techniques/adverse effects"[Mesh]



1
2
3 **Comparative efficacy and complication rates after local treatment for cervical intra-**
4 **epithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and**
5 **network meta-analysis from the CIRCLE Group**
6
7

8 Antonios Athanasiou^{1,2}, Areti Angeliki Veroniki^{1,3}, Orestis Efthimiou⁴, Ilkka Kalliala^{1,5},
9 Huseyin Naci⁶, Sarah Lever^{1,2}, Maria Paraskevaidi¹, Pierre Martin-Hirsch⁷, Philip Bennett^{1,2},
10 Evangelos Paraskevaidis^{2,8}, Georgia Salanti⁴, Maria Kyrgiou^{1,2}
11
12

13
14 ¹Institute of Reproductive and Developmental Biology, Department of Surgery & Cancer,
15 Faculty of Medicine, Imperial College London, UK

16 ²Imperial Healthcare NHS Trust, London, UK

17 ³Department of Primary Education, School of Education, University of Ioannina, Greece

18 ⁴Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg
19 11, 3012 Bern, Switzerland

20 ⁵Department of Obstetrics and Gynaecology, University of Helsinki and Helsinki University
21 Hospital, Finland

22 ⁶Department of Health Policy, London School of Economics & Political Science, UK

23 ⁷Department of Gynaecologic Oncology, Lancashire Teaching Hospitals, Preston, UK

24 ⁸Department of Obstetrics & Gynaecology, University of Ioannina and University Hospital of
25 Ioannina, Greece

26
27
28
29
30
31 AA: a.athanasiou@imperial.ac.uk; AAV: a.veroniki@imperial.ac.uk; OE:
32 oremiou@gmail.com; IK: i.kalliala@imperial.ac.uk; HN: h.naci@lse.ac.uk; SL:
33 s.lever@imperial.ac.uk; MP: m.paraskevaidi@imperial.ac.uk; PMH: [pierre.martin-
35 hirsch@lthtr.nhs.uk](mailto:pierre.martin-
34 hirsch@lthtr.nhs.uk); PB: p.bennett@imperial.ac.uk; EP: eparaske@cc.uoi.gr; GS:
36 georgia.salanti@ispm.unibe.ch; MK: m.kyrgiou@imperial.ac.uk
37
38

39 **Corresponding author:**

40 Maria Kyrgiou, MSc, PhD, MRCOG

41 3rd Floor, IRDB, Department of Surgery & Cancer

42 Imperial College London, Hammersmith Campus

43 Du Cane Road, W12 0NN, London

44 Email: m.kyrgiou@imperial.ac.uk - Tel: +44 2075942177
45
46
47

48 **Word Count:** 3345
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction: Local treatments for cervical intra-epithelial neoplasia (CIN) and micro-invasive disease remove or ablate a cone-shaped part of the uterine cervix containing the abnormal cells. A trend towards less radical techniques has raised concerns that this may adversely impact the rates of precancerous and cancerous recurrence. However, there has been no strong evidence to support such claims. We hereby describe a protocol of a systematic review and network meta-analysis that will update the evidence and compare all relevant treatments in terms of efficacy and complications.

Methods and Analysis: Literature searches in electronic databases (CENTRAL, MEDLINE, EMBASE) or trial registries will identify published and unpublished randomised controlled trials (RCTs) and cohort studies comparing the efficacy and complications amongst different excisional and ablative techniques. The excisional techniques include cold knife, laser or fischer cone, large loop or needle excision of the transformation zone and the ablative radical point diathermy, cryotherapy, cold coagulation or laser ablation. The primary outcome will be residual/recurrent disease defined as abnormal histology or cytology of any grade, while secondary outcomes will include treatment failure rates defined as high-grade histology or cytology, histologically-confirmed CIN1+ or histologically-confirmed CIN2+, HPV positivity rates, involved margins rates, bleeding and cervical stenosis rates. We will assess the risk of bias in RCTs and observational studies using tools developed by the Cochrane Collaboration. Two authors will independently assess study eligibility, abstract the data, and assess the risk of bias. Random-effects meta-analyses and network meta-analyses will be conducted using the odds ratio for dichotomous outcomes and the mean difference for continuous outcomes. The quality of the evidence for the primary outcome will be assessed using the CINEMA tool.

Ethics and dissemination: Ethical approval not required. We will disseminate findings to clinicians, policy makers, patients and the public.

PROSPERO registration number: CRD42018115508

ARTICLE SUMMARY

Strengths and limitations of this study

- We plan to conduct the first network meta-analysis to assess the relative efficacy and complication rates of treatment methods for cervical pre-invasive and early micro-invasive disease.
- This study will produce comprehensive summaries of the clinical ranking of treatments and will employ methodologies that will allow the use of both randomised and observational data, aiming to utilise all published evidence.
- The results will inform clinicians, patients and clinical guidelines and will allow effective patient counselling at colposcopy clinics.
- We expect to find retrospective observational studies at high risk of recall, selection and publication bias. We will try to overcome this limitation by employing methods that aim to minimise bias.

KEYWORDS

"Cervical Intraepithelial Neoplasia/surgery"[Mesh]

"Cervical Intraepithelial Neoplasia/therapy"[Mesh]

"Treatment Outcome"[Mesh]

"Recurrence"[Mesh]

"Conization/adverse effects"[Mesh]

"Ablation Techniques/adverse effects"[Mesh]

INTRODUCTION

Organised screening programmes in countries such as the UK, have led to a dramatic decrease in the incidence and mortality from cervical cancer, especially when compared with the corresponding statistics for the other major cancers. Over a twenty-year period, from 1993-1995 to 2013-2015, the overall age-standardised incidence rate of cancer in females increased by 16% in the UK¹, whereas the corresponding data for cervical cancer showed a decrease of 24%². Cervical cancer is largely preventable through detection and treatment of the pre-invasive precursor, cervical intra-epithelial neoplasia (CIN)³. The local treatment methods are divided into excisional and destructive (ablative) that aim to remove or ablate respectively a cone shaped part of the cervix that contains the 'transformation zone' with the precancerous cells. Although large loop excision of the transformation zone (LLETZ) is the most commonly used methods in the UK⁴ given its ease of execution and low cost, the preference of techniques varies across Europe and internationally.

A Cochrane systematic review of RCTs concluded that all local treatment techniques are highly effective in preventing pre-invasive recurrence⁵. However, this review found no evidence of difference in treatment failure rates amongst the treatment techniques. This could be because the RCTs, and the subsequent meta-analysis might have been underpowered to detect differences between the treatments. The largest study recruited only 390 participants⁶, while the majority of the rest were much smaller. A larger population-based study from Sweden⁷, which included 150,883 women diagnosed and treated for CIN3 (3,148,222 woman-years), reported a doubled standardized incidence ratio for post-treatment invasive recurrence during the follow-up period of around 4 decades in comparison to the general population, and initiated debates on the impact that less radical treatments may have on the subsequent risk of invasion⁸. The trend towards techniques that remove smaller parts of the cervix can be attributed to the fact that many of these are easy to do, they are of low cost, and can be performed in an outpatient setting. Increased awareness of the impact of the more radical or deeper techniques on the risk of prematurity may have also contributed⁹⁻²⁰.

The impact of different techniques on the risk of pre-invasive and/or invasive recurrence remains therefore unclear. With some advocating the minimum radicality of treatment to prevent treatment-induced reproductive morbidity^{10,21}, and others raising concerns about the increase in the risk of future invasion^{7,8}, a definite answer regarding the relative merits and risks among the various treatment strategies is required.

1
2
3 Traditionally, treatment strategies are evaluated via large, expensive trials. Given the possibly
4 comparable (and high) efficacy of most interventions for CIN, it is unlikely that any
5 adequately powered RCT assessing the relative efficacy of different treatment techniques will
6 ever be conducted. Such a trial would require thousands of women in order to reach the
7 statistical power needed to detect differences in the pre-invasive and invasive recurrence
8 rates. In summary, there is currently a lack of adequately powered randomised evidence to
9 allow us to compare the various interventions. However, there is a plethora of available
10 observational studies in the field. These studies are a potentially valuable source of evidence,
11 and may act as a complement to the available randomised evidence, allowing us to more
12 accurately assess the comparative effectiveness and safety of the various treatment
13 alternatives. In this paper, we aim to perform a systematic review of both randomised and
14 observational studies in the field, and quantitatively synthesize their findings in meta-
15 analyses.

16
17
18
19
20
21
22 Systematic reviews and pairwise meta-analyses are widely accepted as a useful tool in
23 comparative effectiveness research, and are commonly used to summarise, critically appraise
24 and synthesise evidence from multiple studies. Investigators aiming to address a research
25 question identify all relevant studies, evaluate their quality, synthesise their findings (meta-
26 analysis) and interpret the provided evidence. Systematic reviews and meta-analyses have
27 played a key role in providing evidence on the efficacy and safety of treatment methods and
28 management strategies in cervical cancer prevention. However, the increased number of
29 management strategies and multiple treatment options requires the use of more advanced
30 evidence-synthesis methods.

31
32
33
34
35 Network meta-analysis (NMA) is an extension of pairwise meta-analysis, for the case when
36 multiple treatments are available for the same condition. NMA has been recognised by the
37 National Institute of Clinical Excellence (NICE)²² and several international Health
38 Technology Assessment (HTA) agencies^{23 24} as a methodological tool that has the potential to
39 increase precision in treatment effect estimates but also to infer on the clinical efficacy/
40 safety between treatments that have never been compared in trials. NMA uses both direct
41 evidence (i.e. coming from studies comparing head-to-head the treatments of interest) and
42 indirect evidence (i.e. coming from studies comparing the treatments of interest via an
43 intermediate common comparator)²⁵⁻²⁸, allows the estimation of relative treatment effects
44 between all available interventions, and provides a clinically useful ranking of the different
45 competing treatments. The methodology of NMA has never been used before to assess the
46 comparative efficacy and complications of different treatment techniques used in the
47 management of CIN. Furthermore, novel NMA methodologies will be employed to allow the
48 use of both randomised and observational data.

49
50
51
52
53
54
55 The aim of this systematic review and NMA is to compare and clinically rank the alternative
56 treatment techniques for CIN based on their efficacy, complications and adverse effects. This
57 NMA forms part of the CIRCLE project (Cervical Cancer Incidence, CIN Recurrence and
58 **R**eproduction after **L**ocal **E**xcision), which aims to generate a clinically useful ranking of
59
60

alternative options for treatment of CIN according to their efficacy (risk of pre-invasive and invasive recurrence), morbidity and cost-effectiveness.

METHODS AND ANALYSIS

This protocol is written in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) (see Supplementary File 1)²⁹.

PROSPERO registration will be updated if we make any amendments to this protocol. The start date was 1st of October 2018 with expected end date 1st of October 2020.

Eligibility criteria of studies

Types of participants

We will include women of all ages treated with local surgical treatment for CIN (or glandular intraepithelial neoplasia) or micro-invasive early cervical cancer (stage IA1). We will only include women with histological diagnosis of CIN on punch biopsy or cone.

Types of interventions

The treatment techniques for cervical intraepithelial neoplasia (CIN) are divided into excisional and ablative. The excisional include cold knife conisation (CKC), laser conisation (LC), needle excision of the transformation zone (NETZ), also known as straight wire excision of the transformation zone (SWETZ), large loop excision of the transformation zone (LLETZ), also known as loop electrosurgical excisional procedure (LEEP) and Fischer cone biopsy excisor (FCBE), while the ablative include radical point diathermy (RD), cryotherapy (CT), cold coagulation (CC) and laser ablation (LA). Figure 1 displays a network example of comparisons between studied treatment techniques. When the treatment is not specified, we will group these under wider categories excision (ENS) or ablation (ANS).

Outcome measures

Primary outcome

- Treatment failure rates defined as any abnormal cytology [ASCUS (atypical squamous cells of undetermined significance) or worse] or histology (CIN1 or worse)

Secondary outcomes

- Treatment failure rates defined as high-grade abnormal cytology [HSIL (high-grade squamous intraepithelial lesion) or worse] or histology (CIN2 or worse)
- Treatment failure rates defined as residual or recurrent histologically-proven CIN1 or worse
- Treatment failure rates defined as residual or recurrent histologically-proven CIN2 or worse
- HPV positivity rates
- Involved margins rates (incomplete excision of the lesion): both, endocervical, ectocervical involvement
- Peri-operative or post-operative bleeding
- Cervical stenosis

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Primary and secondary outcomes were chosen by clinical experts of the team. Treatment failure rates and HPV positivity rates will be reported at 6 to 12 months intervals based on the available data and reported intervals in the included studies.

Types of studies

We will include RCTs, quasi-RCTs and observational cohort studies comparing rates of treatment failure (recurrent/residual disease) or complications amongst the abovementioned surgical techniques. Single-arm studies not presenting a comparison will be excluded. Studies will be considered regardless of time or language.

Information sources and search strategy

The Cochrane Gynaecological Cancer Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE will be searched for eligible studies by an experienced librarian, as presented in Supplementary File 2. Metaregister, Physicians Data Query, www.controlled-trials.com/rct, www.clinicaltrials.gov, www.cancer.gov/clinicaltrials and WHO Registry Network (<https://www.who.int/ictrp/network/en/>) will be searched for ongoing studies. ZETOC (<http://zetoc.mimas.ac.uk>) and WorldCat Dissertations will be searched for conference proceedings and theses, respectively. References of the retrieved articles and meta-analyses will be hand-searched, the “related articles” feature in MEDLINE will be employed and experts in the field will be contacted in an attempt to identify further reports of studies. Corresponding authors will be contacted for any relevant ongoing trials and unpublished data.

We will include both published and unpublished data and there will be no time, place or language restriction; articles in language other than English will be translated using online translation services.

Study selection

Two team members will independently screen titles and abstracts of citations at level 1, using the reference management software Zotero. At level 2, the full text of all potentially eligible articles will be assessed using the same inclusion criteria. Disagreements will be resolved through discussion with a third review author.

Data collection

Data from the included studies will be abstracted at level 3 by two reviewers independently using an a priori developed data collection form in Excel. The following data will be abstracted from the included studies: study characteristics, including author, publication year, country, study design, inclusion/exclusion criteria, and intervention details, participant characteristics, including age, CIN grade and smoking, and dropout rates, and outcome characteristics. In RCTs, we will prefer arm-level data (number of events and sample size per intervention arm for dichotomous data, and mean and standard deviation (SD) per intervention arm for continuous data), but if these are missing, the study-level data will be used in the analysis, e.g. reported odds ratios (ORs) for dichotomous outcomes and mean

1
2
3 differences (MDs) for continuous outcomes, along with a measure of uncertainty (e.g.,
4 confidence interval [CI]). For continuous outcome data not reported as means and standard
5 deviations, we will first contact the corresponding study authors for further information, but
6 if no additional data are provided, we will perform imputation methods to derive approximate
7 effect measures^{30 31}. When an eligible study is observational, we will prefer adjusted
8 treatment effect estimates accounting for the impact of potential confounders, but if these are
9 missing, the unadjusted estimated treatment effects will be abstracted with a corresponding
10 uncertainty measure (e.g. CI). Disagreements will be resolved through consensus or the
11 involvement of a third reviewer.
12
13
14
15

16 **Risk of bias assessment**

17 RCTs will be assessed for quality and risk of bias using the Cochrane risk of bias tool³² in the
18 following domains: randomisation process, deviations from the intended interventions,
19 missing outcome data, measurement of the outcome and selection of the reported result. The
20 risk of bias in each domain, as well as the overall risk of bias, will be rated as “low risk”,
21 “some concerns”, or “high risk”, after answering the signalling questions of each domain
22 with “Yes”, “Potentially Yes”, “Potentially No” or “No”. Non-randomised studies (NRS) will
23 be assessed using the ROBINS-I tool³³ with potential confounding factors: grade of treated
24 CIN, age and smoking. The following domains will be assessed for NRS: confounding,
25 selection of participants into the study, classification of interventions, deviations from
26 intended interventions, missing data, measurement of outcomes and selection of the reported
27 results. The risk of bias in each domain, as well as the overall risk of bias, will be rated as
28 “low”, “moderate”, “serious”, or “critical”, after answering the signalling questions of each
29 domain with “Yes”, “Potentially Yes”, “Potentially No” or “No”. Pairs of team members will
30 independently assess the methodological quality and risk of bias of the eligible studies.
31 Conflicts will be resolved through discussion or with a third investigator. When inadequate
32 information is available from the studies to rate a risk of bias item, we will contact the
33 corresponding study authors for clarification.
34
35
36
37
38
39
40

41 **Statistical synthesis**

42 **Characteristics of included studies and Network**

43 For each outcome, we will produce a network plot (see for example Figure 1) of the available
44 evidence, as well as descriptive statistics, including comparison type, publication year, study
45 design, outcome data, and potential effect modifiers (e.g., age).
46
47
48

49 **Pairwise Meta-analyses**

50 A random-effects meta-analysis will be conducted for each pairwise comparison in each
51 outcome using the inverse variance model and the the Hartung-Knapp-Sidik-Jonkman
52 method to estimate each summary treatment effect and its 95% CI³⁴⁻³⁶. The between-study
53 variance will be estimated with the restricted maximum likelihood estimator, whereas its 95%
54 CI with the Q-profile approach^{34 37 38}. We will also use the I^2 statistic along a 95% CI^{39 40} to
55 evaluate between-study heterogeneity. For continuous outcomes we will report the summary
56 MDs, whereas for dichotomous outcomes we will use the summary ORs, along with a 95%
57 CI. The *metafor* package⁴¹ in R⁴² will be used for all meta-analyses.
58
59
60

Network meta-analyses (NMA)

Data synthesis

A random-effects NMA will be conducted, since we anticipate methodological and clinical between-study heterogeneity. We will assume common between-study variance parameter across treatment comparisons in the network, so that comparisons informed by a single study can borrow strength from the remaining network^{43 44}. This assumption is clinically reasonable because all treatments included in the network of trials are of the same nature. The between-study variance will be estimated with the DerSimonian and Laird method of moments approach⁴⁵. We will employ NMA models that account for different propensity of bias across different study designs as described in Efthimiou et al⁴⁶. We will explore the impact of assigning different levels of credibility and subsequently down-weight the NRS according to experts' opinion and the results of the ROBINS-I tool in several sensitivity analyses.

Similar to the pairwise meta-analysis, for continuous outcomes we will report the estimated MDs, whereas for dichotomous outcomes we will use the estimated ORs, with a 95% CI. Along the 95% CI for the summary effect size, we will report 95% prediction intervals, i.e. the intervals within which the true underlying treatment effect is expected to lie in a new trial⁴⁷. To rank the efficacy for each intervention, we will calculate the ranking probabilities for all treatments, the surface under the cumulative ranking curve (SUCRA) or P-scores, and the mean ranks^{48 49}. A rank-heat plot will be used to depict the SUCRA values or P-scores across all outcomes⁵⁰. We will apply all NMA models in R⁴² using the *netmeta* package⁵¹ and *rjags*⁵² package.

Assessment of the transitivity assumption

One of the prerequisite assumptions in NMA is the transitivity assumption, under which the effect modifiers have a similar distribution across treatment comparisons in a network^{27 53 54}. For the participants characteristics that are described in the inclusion criteria of our systematic review (section type of participants), it is reasonable to assume that all treatments we plan to compare (section type of interventions) are "jointly randomisable". That means that any patient that fulfils that inclusion criteria, could potentially be assigned to any of the interventions. Potential effect modifiers expected to influence the estimated treatment effects include year of study, level of income of study country (as defined by World Bank⁵⁵), method of ascertainment of exposure/outcome (hospital records, registries or interviews/questionnaires), age, smoking and grade of CIN. For each pairwise comparison with available direct evidence we will summarize these characteristics and will visually inspect the similarity of the identified studies. We will also investigate the inclusion and exclusion criteria of all studies, to make sure that patients, treatments and outcomes in the studies are sufficiently similar in all aspects that might modify relative treatment effects. More specifically, we will compare the patient characteristics (such as severity, age, parity etc) across the different treatments. If these characteristics are found to have a similar distribution across treatments then transitivity is supported. If differences are found, then these will be addressed in subgroup and sensitivity analyses.

Assessment of statistical inconsistency

Consistency in a network of trials will be evaluated both locally and globally. We will first assess the consistency assumption locally by separating the direct from the indirect evidence for every comparison in a network to make judgements about their statistical differences, using the back-calculation method⁵⁶. Then we will assess consistency in each network globally using the design-by-treatment interaction model⁵⁷. We will conceptually explore for potential intransitivity in every network even in the absence of evidence for inconsistency, since the inconsistency tests have low power to detect true inconsistency^{58 59}. If no substantial inconsistency is identified in the network of RCTs, we will then evaluate the agreement between RCTs and NRS using the same local and global approaches. Both local (back-calculation method) and global (design-by-treatment interaction model) assessments will be performed under the random-effects model in R⁴² using the *netmeta* package⁵¹.

In the NMA including both RCTs and NRS, we will assess for differences between the different study designs⁴⁶. For each treatment comparison we will summarize evidence by up to four different types: direct randomised, indirect randomised, direct non-randomised and indirect non-randomised. If important discrepancies between these types are found, these will be investigated to confirm that the transitivity assumption holds (e.g. when randomised and non-randomised evidence are very different in terms of populations, interventions, etc., the transitivity assumption may be violated). If disagreement occurs for a certain characteristic, this will be explored through a network meta-regression model²⁶.

Exploring heterogeneity and inconsistency: subgroup analyses and meta-regression

The between-study heterogeneity will be explored by comparing the estimated between-study variance with the empirical distribution derived by Rhodes et al for continuous data⁶⁰ and the one derived by Turner et al for dichotomous data⁶¹. We will also compare 95% CIs with the 95% prediction intervals to infer on the magnitude of the between-study variance.

If at least 10 studies are available, the following potential sources of heterogeneity and/or inconsistency will be explored for the primary outcome using subgroup or meta-regression analyses: year of study, level of income of study country (as defined by World Bank⁵⁵), method of ascertainment of exposure/outcome (hospital records, registries or interviews/questionnaires), age, smoking, grade of CIN, and disease severity (e.g., women treated for high-grade CIN, exclusion of cases of microinvasion). In order to minimise potential bias due to confounding from NRS (e.g. type of treatment or outcome affected by severity), we will also perform a sensitivity analysis excluding NRS without adjusted effect estimates.

Reporting bias and small study effects

We will assess small-study effects by visually exploring the funnel-plot for each treatment, and the comparison adjusted funnel plot⁶² when at least 10 studies are available. We will also conduct a network meta-regression using the study variance as a covariate^{63 64}.

Assessment of the credibility of the evidence

For the primary outcome, two team members will determine the degree of confidence in the estimated NMA results using CINEMA⁶⁵ and the relevant online tool (<http://cinema.ispm.ch/>). The six CINEMA domains, within-study bias (i.e., risk of bias in the included studies), across-study bias (i.e., publication and reporting bias), indirectness, imprecision, heterogeneity and incoherence (i.e., differences between direct and indirect evidence)⁶⁵, will first be rated as high quality, and then they will be downgraded if judged appropriate to moderate, low, or very low quality.

Patient and Public involvement

Patients and the wider public have been involved from the design of this proposal through clinics and the Jo's Cervical Cancer Trust. They have assisted study design and to formulate the research questions. Their involvement will continue throughout the study on regular 6 monthly meetings and will guide the priority questions to be addressed, the development of research reports in lay language and the dissemination of the results.

ETHICS AND DISSEMINATION

We do not require ethical approval for this review. We aim to disseminate the results to clinicians, academic researchers, health agencies and decision makers, to patients and the public. We will publish the results in high impact open access journals and disseminate findings through presentations at medical conferences. The data will become available in public repositories. We will develop information sheets and briefings, highlighting the key findings and circulate newsletters. We will work closely with the Jo's Trust, charity in cervical cancer that frequently organises events to educate the public and also engage the media with interviews. We circulate findings in the Imperial College webpage and will circulate newsletters.

Figure 1. Network of possible pairwise comparisons between eligible treatment methods
Abbreviations: **FCBE**=Fischer cone biopsy excision; **LLETZ**= large loop excision of the transformation zone, also known as **LEEP**=loop electrosurgical excisional procedure; **NETZ**=needle excision of the transformation, also known as **SWETZ**=straight wire excision of the transformation zone; **LC**=laser conisation; **CKC**=cold knife conisation; **LA**=laser ablation; **CC**=cold coagulation; **CT**=cryotherapy; **RD**=radical point diathermy

REFERENCES

1. CancerResearchUK. Cancer incidence for all cancers combined 2018 [Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/all-cancers-combined>].
2. CancerResearchUK. Cervical cancer incidence statistics 2018 [Available from: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer/incidence>].
3. Scarinci IC, Garcia FA, Kobetz E, et al. Cervical cancer prevention: new tools and old barriers. *Cancer* 2010;116(11):2531-42. doi: 10.1002/cncr.25065 [published Online First: 2010/03/24]

- 1
- 2
- 3
- 4 4. NHS. Colposcopy: Treatments 2017 [Available from:
5 <https://www.nhs.uk/conditions/colposcopy/treatment/>.
- 6 5. Martin-Hirsch PP, Paraskevaidis E, Bryant A, et al. Surgery for cervical intraepithelial
7 neoplasia. *Cochrane Database Syst Rev* 2013(12):Cd001318. doi:
8 10.1002/14651858.CD001318.pub3 [published Online First: 2013/12/05]
- 9 6. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy,
10 laser vaporization, and loop electrosurgical excision for treatment of squamous
11 intraepithelial lesions of the cervix. *Obstetrics and gynecology CNO - CN-00156163*
12 1998;92(5 XMAN - MEDLINE 1999008792 XMO - SU XSR - SR-
13 GYNAECA):737-44.
- 14 7. Strander B, Hallgren J, Sparen P. Effect of ageing on cervical or vaginal cancer in Swedish
15 women previously treated for cervical intraepithelial neoplasia grade 3: population
16 based cohort study of long term incidence and mortality. *BMJ* 2014;348:f7361. doi:
17 10.1136/bmj.f7361 [published Online First: 2014/01/16]
- 18 8. Arbyn M, Kyrgiou M, Gondry J, et al. Long term outcomes for women treated for cervical
19 precancer. *Bmj* 2014;348:f7700. doi: 10.1136/bmj.f7700 [published Online First:
20 2014/01/16]
- 21 9. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, et al. Obstetric outcomes after conservative
22 treatment for intraepithelial or early invasive cervical lesions: systematic review and
23 meta-analysis. *Lancet* 2006;367(9509):489-98. doi: 10.1016/s0140-6736(06)68181-6
24 [published Online First: 2006/02/14]
- 25 10. Arbyn M, Kyrgiou M, Simoons C, et al. Perinatal mortality and other severe adverse
26 pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia:
27 meta-analysis. *Bmj* 2008;337:a1284. doi: 10.1136/bmj.a1284 [published Online First:
28 2008/09/20]
- 29 11. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after
30 treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis.
31 *Bmj* 2014;349:g6192. doi: 10.1136/bmj.g6192 [published Online First: 2014/10/30]
- 32 12. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after
33 conservative treatment for cervical intraepithelial neoplasia. *Cochrane Database Syst*
34 *Rev* 2015(9):Cd008478. doi: 10.1002/14651858.CD008478.pub2 [published Online
35 First: 2015/09/30]
- 36 13. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local
37 treatment for cervical preinvasive and early invasive disease according to cone depth:
38 systematic review and meta-analysis. *Bmj* 2016;354:i3633. doi: 10.1136/bmj.i3633
39 [published Online First: 2016/07/30]
- 40 14. Kyrgiou M, Athanasiou A, Kalliala IEJ, et al. Obstetric outcomes after conservative
41 treatment for cervical intraepithelial lesions and early invasive disease. *Cochrane*
42 *Database Syst Rev* 2017;11:Cd012847. doi: 10.1002/14651858.Cd012847 [published
43 Online First: 2017/11/03]
- 44 15. Kyrgiou M, Arbyn M, Martin-Hirsch P, et al. Increased risk of preterm birth after
45 treatment for CIN. *Bmj* 2012;345:e5847. doi: 10.1136/bmj.e5847 [published Online
46 First: 2012/09/07]
- 47 16. Castanon A, Landy R, Brocklehurst P, et al. Risk of preterm delivery with increasing
48 depth of excision for cervical intraepithelial neoplasia in England: nested case-control
49 study. *BMJ* 2014;349:g6223. [published Online First: 2014/11/05]
- 50 17. Noehr B, Jensen A, Frederiksen K, et al. Depth of cervical cone removed by loop
51 electrosurgical excision procedure and subsequent risk of spontaneous preterm
52 delivery. *Obstet Gynecol* 2009;114(6):1232-8. doi: 10.1097/AOG.0b013e3181bf1ef2
53 [published Online First: 2009/11/26]
- 54
- 55
- 56
- 57
- 58
- 59
- 60

18. Khalid S, Dimitriou E, Conroy R, et al. The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. *Bjog* 2012;119(6):685-91. doi: 10.1111/j.1471-0528.2011.03252.x [published Online First: 2012/02/15]
19. Founta C, Arbyn M, Valasoulis G, et al. Proportion of excision and cervical healing after large loop excision of the transformation zone for cervical intraepithelial neoplasia. *Bjog* 2010;117(12):1468-74. doi: 10.1111/j.1471-0528.2010.02709.x [published Online First: 2010/09/16]
20. Kyrgiou M, Valasoulis G, Stasinou SM, et al. Proportion of cervical excision for cervical intraepithelial neoplasia as a predictor of pregnancy outcomes. *Int J Gynaecol Obstet* 2015;128(2):141-7. doi: 10.1016/j.ijgo.2014.07.038 [published Online First: 2014/12/03]
21. Paraskeva E, Kyrgiou M, Martin-Hirsch P. Have we dismissed ablative treatment too soon in colposcopy practice? *Bjog* 2007;114(1):3-4. doi: 10.1111/j.1471-0528.2006.01178.x [published Online First: 2007/01/20]
22. NICE. Developing NICE guidelines: the manual. Process and methods (PMG20). Reviewing research evidence 2017 [Available from: <https://www.nice.org.uk/process/pmg20/chapter/reviewing-research-evidence>].
23. Caldwell DM, Dias S, Welton NJ. Extending Treatment Networks in Health Technology Assessment: How Far Should We Go? *Value Health* 2015;18(5):673-81. doi: 10.1016/j.jval.2015.03.1792 [published Online First: 2015/08/25]
24. CADTH. Network Meta-Analysis 2015 [Available from: <https://www.cadth.ca/network-meta-analysis>].
25. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. *BMJ* 2005;331(7521):897-900. doi: 10.1136/bmj.331.7521.897
26. Salanti G, Marinho V, Higgins JP. A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. *J Clin Epidemiol* 2009;62(8):857-64. doi: 10.1016/j.jclinepi.2008.10.001 [published Online First: 2009/01/20]
27. Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. *Ann Intern Med* 2013;159(2):130-7. doi: 10.7326/0003-4819-159-2-201307160-00008
28. Efthimiou O, Debray TP, van Valkenhoef G, et al. GetReal in network meta-analysis: a review of the methodology. *Res Synth Methods* 2016;7(3):236-63. doi: 10.1002/jrsm.1195 [published Online First: 2016/01/13]
29. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. doi: 10.1186/2046-4053-4-1 [published Online First: 2015/01/03]
30. Furukawa TA, Barbui C, Cipriani A, et al. Imputing missing standard deviations in meta-analyses can provide accurate results. *J Clin Epidemiol* 2006;59(1):7-10. doi: 10.1016/j.jclinepi.2005.06.006 [published Online First: 2005/12/20]
31. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. doi: 10.1136/bmj.d5928 [published Online First: 2011/10/20]
32. Higgins JPT, Sterne JAC, Savović J, et al. A revised tool for assessing risk of bias in randomized trials. In: Chandler J, McKenzie J, Boutron I, et al., eds.: *Cochrane Methods*. Cochrane Database of Systematic Reviews 2016.
33. Sterne JA, Hernan MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;355:i4919. doi: 10.1136/bmj.i4919 [published Online First: 2016/10/14]

- 1
- 2
- 3
- 4 34. Veroniki AA, Jackson D, Viechtbauer W, et al. Methods to estimate the between-study
- 5 variance and its uncertainty in meta-analysis. *Res Synth Methods* 2016;7(1):55-79.
- 6 doi: 10.1002/jrsm.1164 [published Online First: 2015/09/04]
- 7 35. Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials
- 8 with binary outcome. *Stat Med* 2001;20(24):3875-89. [published Online First:
- 9 2002/01/10]
- 10 36. Sidik K, Jonkman JN. A simple confidence interval for meta-analysis. *Stat Med*
- 11 2002;21(21):3153-9. doi: 10.1002/sim.1262 [published Online First: 2002/10/11]
- 12 37. Langan D, Higgins JPT, Jackson D, et al. A comparison of heterogeneity variance
- 13 estimators in simulated random-effects meta-analyses. *Res Synth Methods* 2018 doi:
- 14 10.1002/jrsm.1316 [published Online First: 2018/08/02]
- 15 38. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis.
- 16 *Stat Med* 2007;26(1):37-52. doi: 10.1002/sim.2514 [published Online First:
- 17 2006/02/08]
- 18 39. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses.
- 19 *BMJ* 2003;327(7414):557-60. doi: 10.1136/bmj.327.7414.557 [published Online
- 20 First: 2003/09/06]
- 21 40. Veroniki AA, Jackson D, Viechtbauer W, et al. Recommendations for quantifying the
- 22 uncertainty in the summary intervention effect and estimating the between-study
- 23 heterogeneity variance in random-effects meta-analysis. In: Chandler J, McKenzie J,
- 24 Boutron I, et al., eds.: *Cochrane Methods*. Cochrane Database of Systematic Reviews
- 25 2015.
- 26 41. Viechtbauer W. *Conducting Meta-Analyses in R with the metafor Package*.
- 27 2010;36(3):48.
- 28 42. RDevelopmentCoreTeam. *R: A language and environment for statistical computing*.
- 29 Vienna, Austria: R Foundation for Statistical Computing, 2013.
- 30 43. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. *Stat*
- 31 *Methods Med Res* 2008;17(3):279-301. doi: 10.1177/0962280207080643 [published
- 32 Online First: 2007/10/09]
- 33 44. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. *Stat*
- 34 *Med* 1996;15(24):2733-49. doi: 10.1002/(SICI)1097-
- 35 0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0
- 36 45. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity
- 37 in multivariate meta-analyses. *Stat Med* 2012;31(29):3805-20. doi: 10.1002/sim.5453
- 38 [published Online First: 2012/07/06]
- 39 46. Efthimiou O, Mavridis D, Debray TP, et al. Combining randomized and non-randomized
- 40 evidence in network meta-analysis. *Stat Med* 2017;36(8):1210-26. doi:
- 41 10.1002/sim.7223 [published Online First: 2017/01/14]
- 42 47. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. *BMJ*
- 43 2011;342:d549. doi: 10.1136/bmj.d549 [published Online First: 2011/02/12]
- 44 48. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for
- 45 presenting results from multiple-treatment meta-analysis: an overview and tutorial. *J*
- 46 *Clin Epidemiol* 2011;64(2):163-71. doi: 10.1016/j.jclinepi.2010.03.016 [published
- 47 Online First: 2010/08/05]
- 48 49. Rucker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works
- 49 without resampling methods. *BMC medical research methodology* 2015;15:58. doi:
- 50 10.1186/s12874-015-0060-8 [published Online First: 2015/08/01]
- 51 50. Veroniki AA, Straus SE, Fyraridis A, et al. The rank-heat plot is a novel way to present
- 52 the results from a network meta-analysis including multiple outcomes. *J Clin*
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- Epidemiol* 2016;76:193-9. doi: 10.1016/j.jclinepi.2016.02.016 [published Online First: 2016/03/05]
51. Rücker G, Krahn U, König J, et al. netmeta: Network Meta-Analysis using Frequentist Methods. 2019 [Available from: <https://github.com/guido-s/netmeta> <http://meta-analysis-with-r.org>.]
52. Plummer M. rjags: Bayesian Graphical Models using MCMC. R package version 4-8 2018 [Available from: <https://CRAN.R-project.org/package=rjags>.]
53. Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. *Res Synth Methods* 2012;3(2):80-97. doi: 10.1002/jrsm.1037 [published Online First: 2012/06/11]
54. Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. *BMC Med* 2013;11:159. doi: 10.1186/1741-7015-11-159 [published Online First: 2013/07/04]
55. WorldBank. World Bank list of economies 2019 [Available from: <http://databank.worldbank.org/data/download/site-content/CLASS.xls> accessed May 2019.
56. König J, Krahn U, Binder H. Visualizing the flow of evidence in network meta-analysis and characterizing mixed treatment comparisons. *Stat Med* 2013;32(30):5414-29. doi: 10.1002/sim.6001 [published Online First: 2013/10/15]
57. White IR, Barrett JK, Jackson D, et al. Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression. *Res Synth Methods* 2012;3(2):111-25. doi: 10.1002/jrsm.1045
58. Veroniki AA, Mavridis D, Higgins JP, et al. Characteristics of a loop of evidence that affect detection and estimation of inconsistency: a simulation study. *BMC medical research methodology* 2014;14:106. doi: 10.1186/1471-2288-14-106 [published Online First: 2014/09/23]
59. Song F, Clark A, Bachmann MO, et al. Simulation evaluation of statistical properties of methods for indirect and mixed treatment comparisons. *BMC medical research methodology* 2012;12:138. doi: 10.1186/1471-2288-12-138 [published Online First: 2012/09/14]
60. Rhodes KM, Turner RM, Higgins JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. *J Clin Epidemiol* 2015;68(1):52-60. doi: 10.1016/j.jclinepi.2014.08.012 [published Online First: 2014/10/12]
61. Turner RM, Davey J, Clarke MJ, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews. *Int J Epidemiol* 2012;41(3):818-27. doi: 10.1093/ije/dys041 [published Online First: 2012/03/31]
62. Chaimani A, Higgins JP, Mavridis D, et al. Graphical tools for network meta-analysis in STATA. *PLoS One* 2013;8(10):e76654. doi: 10.1371/journal.pone.0076654 [published Online First: 2013/10/08]
63. Chaimani A, Salanti G. Using network meta-analysis to evaluate the existence of small-study effects in a network of interventions. *Res Synth Methods* 2012;3(2):161-76. doi: 10.1002/jrsm.57 [published Online First: 2012/06/01]
64. Mavridis D, Efthimiou O, Leucht S, et al. Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant. *J Clin Epidemiol* 2016;69:161-9. doi: 10.1016/j.jclinepi.2015.05.027 [published Online First: 2015/07/27]

- 1
2
3 65. Salanti G, Del Giovane C, Chaimani A, et al. Evaluating the quality of evidence from a
4 network meta-analysis. *PLoS One* 2014;9(7):e99682. doi:
5 10.1371/journal.pone.0099682 [published Online First: 2014/07/06]
6
7

8 STATEMENTS

10 Declaration

11 The corresponding author had full access to all the data in the study and the final
12 responsibility for the decision to submit for publication.

13 The senior author MK (the manuscript's guarantor) affirms that the manuscript is an honest,
14 accurate, and transparent account of the study being reported and that no important aspects of
15 the study have been omitted.
16
17
18

19 Author statement

20 The study was conceived and designed by MK, GS and EP. The protocol was drafted by AA,
21 MK, AAV, OE, IK, GS and was revised critically for important intellectual content by all
22 authors (AA, AAV, OE, IK, HN, SL, MP, PMH, PB, EP, GS, MK).
23
24
25

26 Acknowledgements

27 We thank patients and patient representatives for their contribution to designing this study
28 and developing the research questions.
29
30
31

32 Funding statement

33 This work is supported by National Institute for Health Research (NIHR) Research for
34 Patient Benefits (Grant Reference Number PB-PG-0816-20004, P67307). It is also supported
35 by the British Society of Colposcopy Cervical Pathology Jordan/Singer Award (P47773) and
36 the Imperial College Healthcare Charity (P47907)(MK). AAV is funded by the European
37 Union's Horizon 2020 (No 754936). None of the funders have any influence on the study
38 design; in the collection, analysis, and interpretation of data; in the writing of the report; and
39 in the decision to submit the article for publication.
40
41
42
43

44 Competing interests statement

45 We have read and understood BMJ policy on declaration of interests and declare that we have
46 no conflict of interests. All authors have completed the ICMJE uniform disclosure form at
47 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
48 submitted work; no financial relationships with any organisations that might have an interest
49 in the submitted work in the previous three years; no other relationships or activities that
50 could appear to have influenced the submitted work.
51

52 Dr Kyrgiou has received travel and conference expenses, honoraria and consultancy fees for
53 commercial companies (Inovio, MSD etc); these activities are not related to the project.
54
55
56

57 Data sharing



58 No additional data available.
59
60

Copyright statement

“The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.”

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Network of possible pairwise comparisons between eligible treatment methods

117x71mm (300 x 300 DPI)

Supplementary File 1: Reporting checklist for protocol of a systematic review

Based on the PRISMA-P guidelines.

		Reporting Item	Page Number
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	N/A (no previous NMA)
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	14
	#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	4
Sources	#5a	Indicate sources of financial or other support for the review	15
Sponsor	#5b	Provide name for the review funder and / or sponsor	15
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	15
Rationale	#6	Describe the rationale for the review in the context of what is already known	3-4
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	5

1	Information	#9	Describe all intended information sources (such as electronic	5-6
2	sources		databases, contact with study authors, trial registers or other	
3			grey literature sources) with planned dates of coverage	
4				
5				
6	Search strategy	#10	Present draft of search strategy to be used for at least one	5;
7			electronic database, including planned limits, such that it could	Supplementary
8			be repeated	File 2
9				
10				
11	Study records -	#11a	Describe the mechanism(s) that will be used to manage records	6
12	data management		and data throughout the review	
13				
14				
15	Study records -	#11b	State the process that will be used for selecting studies (such as	6
16	selection process		two independent reviewers) through each phase of the review	
17			(that is, screening, eligibility and inclusion in meta-analysis)	
18				
19				
20				
21	Study records -	#11c	Describe planned method of extracting data from reports (such	6
22	data collection		as piloting forms, done independently, in duplicate), any	
23	process		processes for obtaining and confirming data from investigators	
24				
25				
26	Data items	#12	List and define all variables for which data will be sought (such	6
27			as PICO items, funding sources), any pre-planned data	
28			assumptions and simplifications	
29				
30				
31	Outcomes and	#13	List and define all outcomes for which data will be sought,	5
32	prioritization		including prioritization of main and additional outcomes, with	
33			rationale	
34				
35				
36				
37	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	6-7
38	individual studies		individual studies, including whether this will be done at the	
39			outcome or study level, or both; state how this information will	
40			be used in data synthesis	
41				
42				
43	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	7
44			synthesised	
45				
46				
47		#15b	If data are appropriate for quantitative synthesis, describe	7-8
48			planned summary measures, methods of handling data and	
49			methods of combining data from studies, including any planned	
50			exploration of consistency (such as I ² , Kendall's τ)	
51				
52				
53				
54		#15c	Describe any proposed additional analyses (such as sensitivity	8-9
55			or subgroup analyses, meta-regression)	
56				
57				
58		#15d	If quantitative synthesis is not appropriate, describe the type of	N/A
59				
60				

summary planned

1			
2			
3	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as 9
4			publication bias across studies, selective reporting within
5			studies)
6			
7			
8	Confidence in	#17	Describe how the strength of the body of evidence will be 9
9	cumulative		assessed (such as GRADE)
10	evidence		
11			
12			

13 The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY
14 4.0. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR](#)
15 [Network](#) in collaboration with [Penelope.ai](#)
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary File 2: Search algorithms

Medline Ovid RCT only

- 1 exp Cervical Intraepithelial Neoplasia/
- 2 CIN.mp.
- 3 (cervi* and (intraepithel* or epithel*)).mp.
- 4 (cervi* and dysplasia).mp.
- 5 (cervi* and carcinoma in situ).mp.
- 6 (cervi* and cancer in situ).mp.
- 7 (cervi* and (precancer* or pre-cancer*)).mp.
- 8 1 or 2 or 3 or 4 or 5 or 6 or 7
- 9 surgery.fs.
- 10 exp Gynecologic Surgical Procedures/
- 11 (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
or transformation zone or LLETZ or LEEP).mp.
- 12 9 or 10 or 11
- 13 8 and 12
- 14 randomized controlled trial.pt.
- 15 controlled clinical trial.pt.
- 16 randomized.ab.
- 17 placebo.ab.
- 18 clinical trials as topic.sh.
- 19 randomly.ab.
- 20 trial.ti.
- 21 14 or 15 or 16 or 17 or 18 or 19 or 20
- 22 13 and 21

Medline Ovid NON RCT only

1. exp Cervical Intraepithelial Neoplasia/
2. CIN.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
3. (cervi* and (intraepithel* or epithel*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
4. (cervi* and dysplasia).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

- 1
- 2
- 3
- 4 5. (cervi* and carcinoma in situ).mp. [mp=title, abstract, original title, name of
- 5 substance word, subject heading word, keyword heading word, protocol
- 6 supplementary concept word, rare disease supplementary concept word, unique
- 7 identifier, synonyms]
- 8
- 9 6. (cervi* and cancer in situ).mp. [mp=title, abstract, original title, name of substance
- 10 word, subject heading word, keyword heading word, protocol supplementary concept
- 11 word, rare disease supplementary concept word, unique identifier, synonyms]
- 12
- 13 7. (cervi* and (precancer* or pre-cancer*)).mp. [mp=title, abstract, original title,
- 14 name of substance word, subject heading word, keyword heading word, protocol
- 15 supplementary concept word, rare disease supplementary concept word, unique
- 16 identifier, synonyms]
- 17
- 18 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 19
- 20 9. surgery.fs.
- 21
- 22 10. exp Gynecologic Surgical Procedures/
- 23
- 24 11. (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
- 25 or transformation zone or LLETZ or LEEP).mp. [mp=title, abstract, original title,
- 26 name of substance word, subject heading word, keyword heading word, protocol
- 27 supplementary concept word, rare disease supplementary concept word, unique
- 28 identifier, synonyms]
- 29
- 30 12. 9 or 10 or 11
- 31
- 32 13. 8 and 12
- 33
- 34 14. randomized controlled trial.pt.
- 35
- 36 15. controlled clinical trial.pt.
- 37
- 38 16. randomized.ab.
- 39
- 40 17. placebo.ab.
- 41
- 42 18. clinical trials as topic.sh.
- 43
- 44 19. randomly.ab.
- 45
- 46 20. trial.ti.
- 47
- 48 21. groups.ab.
- 49
- 50 22. exp cohort studies/
- 51
- 52 23. exp case-control studies/
- 53 24. (cohort* or prospective* or retrospective* or (case* and (control* or series))).mp.
- 54
- 55 25. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24
- 56
- 57 26. (animals not (humans and animals)).sh.
- 58
- 59 27. 25 not 26
- 60 28. 13 and 27

Embase Ovid RCT only

- 1 exp Uterine Cervix Carcinoma in Situ/

- 1
2
3
4 2 CIN.mp.
5 3 (cervi* and (intraepithel* or epithel*)).mp.
6
7 4 (cervi* and dysplasia).mp.
8
9 5 (cervi* and carcinoma in situ).mp.
10
11 6 (cervi* and cancer in situ).mp.
12
13 7 (cervi* and (precancer* or pre-cancer*)).mp.
14
15 8 1 or 2 or 3 or 4 or 5 or 6 or 7
16
17 9 su.fs.
18
19 10 exp gynecologic surgery/
20
21 11 (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
22
23 or transformation zone or LLETZ or LEEP).mp.
24
25 12 9 or 10 or 11
26
27 13 8 and 12
28
29 14 crossover procedure/
30
31 15 double-blind procedure/
32
33 16 randomized controlled trial/
34
35 17 single-blind procedure/
36
37 18 random*.mp.
38
39 19 factorial*.mp.
40
41 20 (crossover* or cross over* or cross-over*).mp.
42
43 21 placebo*.mp.
44
45 22 (double* adj blind*).mp.
46
47 23 (singl* adj blind*).mp.
48
49 24 assign*.mp.
50
51 25 allocat*.mp.
52
53 26 volunteer*.mp.
54
55 27 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
56
57 28 13 and 27
58
59
60

Embase Ovid All Studies

1. exp Uterine Cervix Carcinoma in Situ/
2. CIN.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]
3. (cervi* and (intraepithel* or epithel*)).mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword, floating subheading word]

- 1
- 2
- 3
- 4 4. (cervi* and dysplasia).mp. [mp=title, abstract, heading word, drug trade name,
- 5 original title, device manufacturer, drug manufacturer, device trade name, keyword,
- 6 floating subheading word]
- 7
- 8 5. (cervi* and carcinoma in situ).mp. [mp=title, abstract, heading word, drug trade
- 9 name, original title, device manufacturer, drug manufacturer, device trade name,
- 10 keyword, floating subheading word]
- 11
- 12 6. (cervi* and cancer in situ).mp. [mp=title, abstract, heading word, drug trade name,
- 13 original title, device manufacturer, drug manufacturer, device trade name, keyword,
- 14 floating subheading word]
- 15
- 16 7. (cervi* and (precancer* or pre-cancer*)).mp. [mp=title, abstract, heading word,
- 17 drug trade name, original title, device manufacturer, drug manufacturer, device trade
- 18 name, keyword, floating subheading word]
- 19
- 20 8. 1 or 2 or 3 or 4 or 5 or 6 or 7
- 21
- 22 9. su.fs.
- 23
- 24 10. exp gynecologic surgery/
- 25
- 26 11. (surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
- 27 or transformation zone or LLETZ or LEEP).mp.
- 28
- 29 12. 9 or 10 or 11
- 30
- 31 13. 8 and 12
- 32
- 33 14. exp controlled clinical trial/
- 34
- 35 15. randomized.ab.
- 36
- 37 16. randomly.ab.
- 38
- 39 17. trial.ab.
- 40
- 41 18. groups.ab.
- 42
- 43 19. exp cohort analysis/
- 44
- 45 20. cohort*.mp.
- 46
- 47 21. exp retrospective study/
- 48
- 49 22. exp prospective study/
- 50
- 51 23. (case* and series).mp.
- 52
- 53 24. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
- 54
- 55 25. 13 and 24

56 CENTRAL

- 57 #1 MeSH descriptor Cervical Intraepithelial Neoplasia explode all trees
- 58 #2 CIN
- 59 #3 cervi* and (intraepithel* or epithel*)
- 60 #4 cervi* and dysplasia
- #5 cervi* and carcinoma in situ
- #6 cervi* and cancer in situ
- #7 cervi* and (precancer* or pre-cancer*)
- #8 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7)

1
2
3 #9 Any MeSH descriptor with qualifier(s): [Surgery - SU]
4 #10 MeSH descriptor: [Gynecologic Surgical Procedures] explode all trees
5 #11 surg* or ablat* or excis* or cryotherapy or laser* or cone or conisation or biopsy
6 or transformation zone or LLETZ or LEEP
7
8 #12 #9 or #10 or #11
9 #13 #8 and #12
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only